Gan to kagaku ryoho. Cancer & chemotherapy · 2026
[Three Cases of Encorafenib Treatment for Recurrent BRAF-Mutated Colorectal Cancer].
СтатьяКлинический случайАннотация на английскомНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ozasa Haruka, Nanishi Kenji, Arita Tomohiro, Shimizu Hiroki, Kiuchi Jun, Kurashima Kento, Inoue Hiroyuki, Nishibeppu Keiji, Kubo Hidemasa, Imamura Taisuke, Kosuga Toshiyuki, Yamamoto Yusuke, Konishi Hirotaka, Morimura Ryo, Fujiwara Hitoshi, Shiozaki Atsushi
Аннотация
BACKGROUND: Recently, favorable outcomes from encorafenib treatment have been reported in patients with BRAF-mutated colorectal cancer, which has a poor prognosis.
CASES: Encorafenib was administered to three patients with recurrence after surgery for BRAF-mutated colorectal cancer. Encorafenib and cetuximab were administered to 2 patients, and encorafenib, binimetinib, and cetuximab were administered to one patient. In all cases, tumor markers decreased, and the metastatic tumors shrank. No severe adverse effects were observed.
DISCUSSION: BRAF-mutated colorectal cancer often occurs in the right colon. It is also common in older patients, women, and patients with poorly differentiated tumors; our cases exhibited similar characteristics. As previously reported, both doublet and triplet encorafenib treatments are safe and effective.
CONCLUSION: Combination therapy with encorafenib was effective for the treatment of recurrent BRAF-mutated colorectal cancer, showing good tumor control with few adverse effects. Therefore, this may be a useful treatment option.
CASES: Encorafenib was administered to three patients with recurrence after surgery for BRAF-mutated colorectal cancer. Encorafenib and cetuximab were administered to 2 patients, and encorafenib, binimetinib, and cetuximab were administered to one patient. In all cases, tumor markers decreased, and the metastatic tumors shrank. No severe adverse effects were observed.
DISCUSSION: BRAF-mutated colorectal cancer often occurs in the right colon. It is also common in older patients, women, and patients with poorly differentiated tumors; our cases exhibited similar characteristics. As previously reported, both doublet and triplet encorafenib treatments are safe and effective.
CONCLUSION: Combination therapy with encorafenib was effective for the treatment of recurrent BRAF-mutated colorectal cancer, showing good tumor control with few adverse effects. Therefore, this may be a useful treatment option.